Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Expenses
Research and development	$ 592	$ 2,005	$ 2,562	$ 7,235
General and administrative	1,493	1,297	3,504	4,212
Operating expenses	(2,085)	(3,302)	(6,066)	(11,447)
Other income (loss)
Foreign exchange	0	(1)	(8)	10
Interest, net	74	39	78	123
Other income (loss)	74	38	70	133
Net loss for the period	(2,011)	(3,264)	(5,996)	(11,314)
Computation of basic loss per share
Net loss	(2,011)	(3,264)	(5,996)	(11,314)
Series A Preferred cash dividend	(2)	(2)	(6)	(6)
Net loss for the period attributable to common stockholders	$ (2,013)	$ (3,266)	$ (6,175)	$ (11,682)
Basic and fully diluted loss per share	$ (0.05)	$ (1.94)	$ (0.37)	$ (7.32)
Basic and fully diluted weighted average number of shares	44,562,000	1,681,000	16,772,000	1,596,000
Preferred Stock Series C
Computation of basic loss per share
Preferred stock dividend			$ (173)	$ (362)